James V. Caggiano

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Dendreon Pharmaceuticals, Inc. discovers, develops and commercializes novel products for the treatment of cancer. The company is headquartered in Olympia, WA.

Targazyme, Inc. operates as a biotechnology company. It develops and commercializes breakthrough products. The firm offers products for stem cell transplantation, immunotherapy for cancer, regenerative medicine, and gene therapy. The company was founded by Lynnet Koh and is headquartered in Carlsbad, CA.

Evolve Biologics, Inc. is a Canadian plasma-derived therapeutics company headquartered in Mississauga, CA. The company is focused on commercializing a portfolio of product candidates, including intravenous immunoglobulin (IVIG) and human serum albumin (HSA), both of which are in advanced stages of regulatory approval with the FDA and Health Canada. Evolve's state-of-the-art facility is the first to use its innovative and proprietary technology, Plasmacap EBA®, to commercially produce plasma-derived therapeutics. The company has recently appointed James V. Caggiano as CEO, who brings nearly 30 years of experience in the biotech, pharma, and medical device industries.